Search

Previous studies have reported on the relationship between gut microbiota and major depressive disorder (MDD). However, there remain gaps in literature concerning the role of the intestinal barrier and microflora in the pathogenesis of depression. This study analyzes the potential causative relationship between gut microbiota and inflammatory and gut integrity markers and clinical symptoms in inpatients with depressive episodes. Sixteen inpatients (50% females) being treated with escitalopram (5–20 mg daily) in standardized conditions were included in the study. The composition of fecal microbiota was evaluated at baseline and endpoint using 16S rRNA sequencing. A significant correlation between depression severity was found, as measured with HDRS24 (Hamilton Depression Rating Scale-24 item), and the following abundance in bacteria: positive correlation with Paraprevotella (r = 0.80, q = 0.012), strong, negative correlations with Clostridiales (r = −0.70, q = 0.016), Clostridia (r = −0.71, q = 0.026), Firmicutes (r = −0.67. q = 0.032), and the RF32 order (r = −0.70, p = 0.016) in the Alphaproteobacteria (r = −0.66, q = 0.031). After six weeks of treatment, clinical outcomes were found to have a negative correlation with levels of plasma intestinal fatty acid-binding protein (IFABP) at the beginning of the study. Still they had a positive correlation with changes in fecal calprotectin during hospitalization. In conclusion, gut microbiota was associated with the severity of depressive symptoms. However, these findings do not serve as predictors of symptomatic improvement during antidepressant treatment in inpatient treatment for MDD. In turn, intestinal integrity and inflammation markers were associated with the response to treatment of patients with MDD and symptom severity. Additional studies are needed to confirm and extend these findings.

Rationale: There is a worldwide prevalence of generalized anxiety and major depressive disorders (MDD). Gut&ndash, brain axis dysfunction, antibacterial activity, and modulatory effects of antidepressants toward intestinal bacteria have been shown both in vitro and in vivo. Objectives: In this study, we aimed to investigate the effects of hospital stay, including escitalopram administration, on gut microbiota in patients with depressive episodes. Methods: After admission to the hospital and 7-days washout from all medications the composition of fecal microbiota samples was evaluated at baseline (W0) and after 6 weeks (W6), using 16S rRNA sequencing. The study was conducted on 17 inpatients (52.9% females), who followed the same daily hospital routine, including a standard diet and received 5&ndash, 20 mg daily doses of escitalopram. Results: At the end of treatment (W6), no change was observed in the Chao1 index. However, Shannon (median (Q1&ndash, Q3): W0 2.78 (2.67&ndash, 3.02) vs. W6 3.11 (2.80&ndash, 3.30)), and inverse Simpson (median (Q1&ndash, Q3): W0 9.26 (7.26&ndash, 13.76) vs. W6 12.13 (9.17&ndash, 15.73)) indices increased significantly compared to baseline values (False Discovery Rate p (q) = 0.031 and q = 0.011, respectively). We also found that between-subject W0 Bray&ndash, Curtis dissimilarities were significantly higher than W0&ndash, W6 within-subject dissimilarities (median (Q1&ndash, Q3): 0.68 (0.56&ndash, 0.77) vs. 0.38 (0.35&ndash, 0.52), two sided Mann&ndash, Whitney test p &lt, 0.00001. The within-subject dissimilarities did not depend on sex, age, BMI, illness duration and a daily dose of escitalopram. No significant differences between taxa levels, at the studied time points, were observed when adjusted for multiple hypotheses testing procedures. Conclusions: We conclude that a six-week treatment in a psychiatric hospital setting resulted in increased alpha biodiversity in fecal microbiota, however its causal relationship with patients&rsquo, mental health was not proved. We have also found that individual microbiome stability was not affected by hospitalization.

The problem of eating disorders was described in literature for the first time at the end of the 17th century. Nowadays, the term eating disorders means adisturbance to eating habits for which the common denominator is, among others, a characteristic way of thinking and behaviors observed in people who are ill. Anorexia is a disorder increasingly observed among young people, but in fact the problem of eating disorders affects each age group and gender, and this aspect is presented in the following article.

TWstęp: W niniejszym artykule przedstawiono przypadek pacjentki chorującej na organiczne zaburzenia urojeniowe. Początek objawów psychiatrycznych następował stopniowo w okresie kilku tygodni po przeszczepieniu pacjentce nerki od zmarłego dawcy.Opis przypadku: 42-letnia pacjentka została przyjęta na oddział psychiatrii w celu obserwacji stanu psychicznego oraz ewentualnej modyfikacji postawionego wcześniej rozpoznania klinicznego.Komentarz: Objawy psychotyczne o charakterze urojeń ksobnych, prześladowczych oraz omamów słuchowych pojawiły się u pacjentki w okresie kilku tygodni po przeszczepie nerki od zmarłego dawcy. Objawy te miały tendencję do stopniowego nasilania się. Zgodnie ze standardami postępowania potransplantacyjnego pacjentka przyjmowała zwiększone dawki leków immunosupresyjnych, jednak mimo redukcji dawek objawy psychotyczne nie uległy zmniejszeniu. Pacjentka obciążona była somatycznie chorobą Hashimoto, nadciśnieniem tętniczym, wirusowym zapaleniem wątroby typu B, zakrzepicą tętnicy szyjnej wewnętrznej, cukrzycą typu 2 powikłaną nefropatią, retinopatią i neuropatią.Wnioski: Przedstawiony przypadek stanowi przykład wielo­czynnikowej etiologii objawów psychopatologicznych oraz wskazuje na konieczność uwzględniania wielu aspektów stanu somatycznego przy ustalaniu diagnozy psychiatrycznej i planowaniu leczenia pacjenta.

Accumulating evidence indicates the potential effect of microbiota on the pathogenesis and course of schizophrenia. However, the effects of olanzapine, second-generation antipsychotics, on gut microbiota have not been investigated in humans. This study aimed to analyze fecal microbiota in schizophrenia patients treated with olanzapine during six weeks of their hospital stay. After a seven-day washout from all psychotropic medications, microbiota compositions were evaluated at baseline and after six weeks of hospitalization using 16S rRNA sequencing. The study was conducted in 20 inpatients, who followed the same hospital routine and received 5&ndash, 20 mg daily doses of olanzapine. Olanzapine treatment was associated with clinical improvements in all patients and significant increases in body mass index in females, but not changes in gut microbiota compositions and predicted function. The severity of symptoms at the beginning of treatment varied in accordance with the predicted metabolic activity of the bacteria. The present findings indicate that the microbiota of schizophrenia patients is highly individual and has different taxonomical (Type 1, with a predominance of Prevotella, and Type 2 with a higher abundance of Bacteroides, Blautia and Clostridium) and functional clusters, and it does not change following six weeks of olanzapine therapy, in addition, the microbiota is not associated with either the weight gain observed in women or the effectiveness of olanzapine therapy.